Khiron Life Sciences Hosts Canadian Pavilion at Cannamexico World Summit 2019, Targeting over 2,000 Global Cannabusiness Leaders

  • One of the largest and most influential cannabis conferences in Latin America
  • Two-day conference to attract over 2,000 attendees from more than ten countries
  • First Canadian Pavilion welcomes prominent Canadian and global cannabis industry leaders
  • Canadian Pavilion partners include MNP, Cardiol Therapeutics Inc., BMO and Dixie Brands. As previously announced, Dixie Brands and Khiron have established a joint venture to bring Dixie Brands’ 100+ category-leading SKU’s to the Latin American marketplace
  • Summit co-hosted by Vicente Fox, 55th President of Mexico, former CEO of Coca-Cola Mexico and Khiron board member
  • Summit offers timely opportunity for investors and industry to understand the regulatory environment for the imminent Mexican cannabis market

TORONTO, April 4, 2019 /PRNewswire/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America, announced today that it will co-host the Canadian Pavilion at Cannamexico World Summit 2019, one of the largest and most influential cannabis conferences in Latin America. The Canadian Pavilion brings together industry leaders to discuss innovation and development opportunities and the important role for Canadian business on the cannabis world stage. In addition to Khiron, key Canadian Pavilion partners include MNP, Cardiol Therapeutics Inc., BMO and Dixie Brands.  As previously announced, Dixie Brands and Khiron have established a joint venture to bring Dixie Brands’ 100+ category-leading SKU’s to the Latin American marketplace.

Alvaro Torres, CEO and a Director of Khiron, comments: ” Cannamexico and the Canadian Pavilion provide an essential forum to discuss the fast developing market opportunity in Mexico with leading stakeholders. Mexico is an important jurisdiction for Khiron as we continue to execute on our strategy to be a market leader across Latin America. We look forward to welcoming industry colleagues and the cannabis community to the Canadian Pavilion at Cannamexico to help build a strong and secure cannabis industry in Mexico.”

Vicente Fox, former president of Mexico and Khiron board member, comments: ” The first Canadian Pavilion will be an exclusive space dedicated to showcasing leading Canadian cannabusinesses and offers a unique opportunity to showcase business, meet with leading global stakeholders, and gain valuable knowledge about business opportunities in the Mexican and Latin American cannabis industry.”

The Cannamexico World Summit 2019, taking place April 25-26 in Guanajuato, Mexico, is presented by CentroFox and Khiron Life Sciences. Cannamexico is a global summit focused on showcasing the potential for the Cannabis industry in Mexico, a market estimated at 2 Billion USD (Source: Prohibition Partners). The summit brings together regional and global cannabis leaders to discuss regulatory developments, market opportunities, medical advances, innovation, and wellness for the LatAm cannabis industry. For more information visit the website:

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both THC (tetrahydrocannabinol) and CBD (cannabidiol) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally. 

With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox. 

Further information on Khiron Life Sciences can be found at

To be added to the distribution list, please email with “Khiron” in the subject line.


Market and Industry Data

This press release contains market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this press release, or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources.

Forward-Looking Statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Forward-looking statements may be identified by  statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. Forward-looking statements herein include, but are not limited to, statements regarding the anticipated benefits of the distribution agreements, including online and physical retail consumer exposure, and potential expansion into other jurisdictions, among others. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.